Biotech co Savara falls after $130 mln equity offering

Savara

30/10/2025 13:27

** Savara Inc SVRA.O shares down 4.4% premarket to $4.15 after $130 mln overnight follow-on priced

** Langhorne, Pennsylvania-based SVRA late Weds sold ~31 mln shares, including ~7.1 mln prefunded warrants

** Offering price of $4.20 is 3.2% discount to stock's last sale

** It plans to use net offering proceeds for general corporate purposes, which include funding of clinical development, pursuing regulatory approval of Molbreevi

** Co's lead program, Molbreevi, is in Phase 3 development for potential treatment of autoimmune pulmonary alveolar proteinosis (autoimmune PAP), a rare lung disease

** SVRA has ~172.8 mln shares outstanding

** Jefferies, Piper Sandler and Guggenheim are joint bookrunners for offering

** Through Weds close, stock up 41% YTD

** 3 analysts rate the stock "strong buy" and 5 rate "buy"; median PT of $10.75 up from $8 a month ago, per LSEG

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))